Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
217
datasets available to search
ShareScore release 0.9.0
Dataset results
217 results for “Rheumatic Diseases”
IMBALANCED MACHINE LEARNING CLASSIFICATION MODELS FOR REMOVAL BIOSIMILAR DRUGS AND INCREASED ACTIVITY IN PATIENTS WITH RHEUMATIC DISEASES
<p>Objective: Predict long-term disease worsening and the removal of biosimilar medication in patients with rheumatic diseases.</p><p>Methodology: Observational, retrospective, and descriptive study. Review of a database of patients with immune-mediated inflammatory rheumatic diseases. Disease worsening and removing biosimilars are imbalanced variables, that require using imbalanced machine learning models selected based on their superior f1-scores and great accuracy. Previously, we selected the most important variables using mutual information tests.</p><p>Results: The best imbalanced machine learning models to predict disease worsening and the removal of the biosimilar obtained f1-scores of 0.52 and 0.63, respectively. Both models are decision trees. In the first one, two important factors are switching of biosimilar and age, and in the second, the relevant variables are optimization and the value of the initial CRP. </p><p>Conclusions: Biosimilar drugs do not always work well for rheumatic diseases. We obtained two imbalanced machine learning models to detect those cases, where the drug should be removed or where the activity of the disease increases from low to high. Our decision trees use variables, such as age or switching, not considered in previous studies.</p>
Antibodies to Borrelia burgdorferi and Bartonella species in serum and synovial fluid from people with rheumatic diseases
<p>Vector-borne infections may underlie some rheumatic diseases, particularly in people with joint effusions. The aim of this study was to compare serum and synovial fluid antibodies to<em> B. burgdorferi </em>and <em>Bartonella </em>spp. in patients with rheumatic diseases.</p> <p>This observational, cross-sectional study examined paired synovial fluid and serum specimens collected from 110 patients with joint effusion between October 2017 and January 2022. Testing for antibodies to <em>B. burgdorferi </em>(using CDC criteria) and <em>Bartonella </em>spp. via two Indirect Fluorescent Antibody [IFA] assays, was performed as part of routine patient care.</p> <p>There were 30 participants (27%) with positive two-tier <em>B. burgdorferi</em> serology, and 26 participants (24%) with IFA seroreactivity (≥1:256) to <em>B. henselae </em>and/or <em>B. quintana. </em>Both <em>B. burgdorferi</em> IgM and IgG were detected more frequently in synovial fluid than serum: 27% of patients were either IgM or IgG positive in synovial fluid, compared to 15.5% in serum (p = 0.048). Conversely, <em>B. henselae </em>and <em>B. quintana </em>antibodies were detected more frequently in serum than synovial fluid; overall only 2% of patients had positive IFA titers in synovial fluid, compared to 24% who had positive IFA titers in serum (p <0.001). There were no significant associations between <em>B. burgdorferi</em> or <em>Bartonella</em> spp. seroreactivity with any of the clinical rheumatological diagnoses.</p> <p>This study provides preliminary support for the importance of synovial fluid antibody testing for documenting exposure to <em>B. burgdorferi</em>, but not for documenting exposure to <em>Bartonella </em>spp.</p>
Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial
ClinicalTrials.gov study NCT04776161. IPD Sharing: NO. Countries: 1. Publications: 1.
CPAP Treatment and Postoperative Outcomes in Patients With Rheumatic Valvular Heart Disease
ClinicalTrials.gov study NCT03398733. IPD Sharing: NO. Countries: 1. Publications: 2.
INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs
ClinicalTrials.gov study NCT00902486. IPD Sharing: Not stated. Countries: 2. Publications: 3.
MyVoice:Rheum Decision Aid for Women With Rheumatic Diseases
ClinicalTrials.gov study NCT04879745. IPD Sharing: NO. Countries: 1. Publications: 31.
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and H
ClinicalTrials.gov study NCT02720523. IPD Sharing: YES. Countries: 1. Publications: 3.
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
ClinicalTrials.gov study NCT01490450. IPD Sharing: Not stated. Countries: 13. Publications: 1.
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
ClinicalTrials.gov study NCT03122431. IPD Sharing: NO. Countries: 1. Publications: 20.
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic
ClinicalTrials.gov study NCT03104374. IPD Sharing: YES. Countries: 19. Publications: 14.
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
ClinicalTrials.gov study NCT02873936. IPD Sharing: NO. Countries: 15. Publications: 7.
A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
ClinicalTrials.gov study NCT02046616. IPD Sharing: Not stated. Countries: 4. Publications: 4.
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
ClinicalTrials.gov study NCT01941095. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Antibodies to Borrelia burgdorferi and Bartonella species in serum and synovial fluid from people with rheumatic diseases
Open the record for dataset details and reuse information.
Dataset related to article "Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases"
<p>This record contains data related to article “Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases”</p> <p>The purpose of this study was to evaluate the efficacy and safety of the Moderna-1273 mRNA vaccine for SARS-CoV-2 in patients with immune-mediated diseases under different treatments. Anti-trimeric spike protein antibodies were tested in 287 patients with rheumatic or autoimmune diseases (10% receiving mycophenolate mofetil, 15% low-dose glucocorticoids, 21% methotrexate, and 58% biologic/targeted synthetic drugs) at baseline and in 219 (76%) 4 weeks after the second Moderna-1273 mRNA vaccine dose. Family members or caretakers were enrolled as the controls. The neutralizing serum activity against SARS-CoV-2-G614, alpha, and beta variants in vitro and the cytotoxic T cell response to SARS-CoV-2 peptides were determined in a subgroup of patients and controls. Anti-SARS-CoV-2 antibody development, i.e., seroconversion, was observed in 69% of the mycophenolate-treated patients compared to 100% of both the patients taking other treatments and the controls (<em>p</em> &lt; 0.0001). A dose-dependent impairment of the humoral response was observed in the mycophenolate-treated patients. A daily dose of &gt;1 g at vaccination was a significant risk factor for non-seroconversion (ROC AUC 0.89, 95% CI 0.80-98, <em>p</em> &lt; 0.0001). Moreover, in the seroconverted patients, a daily dose of &gt;1 g of mycophenolate was associated with significantly lower anti-SARS-CoV-2 antibody titers, showing slightly reduced neutralizing serum activity but a comparable cytotoxic response compared to other immunosuppressants. In non-seroconverted patients treated with mycophenolate at a daily dose of &gt;1 g, the cytotoxic activity elicited by viral peptides was also impaired. Mycophenolate treatment affects the Moderna-1273 mRNA vaccine immunogenicity in a dose-dependent manner, independent of rheumatological disease.</p> <p>.</p>
The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa
ClinicalTrials.gov study NCT04556188. IPD Sharing: UNDECIDED. Countries: 2. Publications: 1.
Prevalence of Rheumatic Heart Disease According to Revised Jones Criteria (2015) in Assiut Governate
ClinicalTrials.gov study NCT04316897. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Impact of a Telenursing Service on Satisfaction and Health Outcomes of Children With Inflammatory Rheumatic Diseases
ClinicalTrials.gov study NCT01511341. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Yellow Fever Vaccine in Patients With Rheumatic Diseases
ClinicalTrials.gov study NCT03430388. IPD Sharing: UNDECIDED. Countries: 1. Publications: 38.
Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate
ClinicalTrials.gov study NCT04042792. IPD Sharing: Not stated. Countries: 2. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.